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High fat dieta b s t r a c t
Studies in sarcolipin knockout mice have led to the suggestion that skeletal muscle sarcolipin plays a role
in thermogenesis. The mechanism proposed is uncoupling of the sarcoplasmic reticulum calcium pump.
However, in other work sarcolipin was not detected in mouse skeletal tissue. We have therefore mea-
sured sarcolipin levels in mouse skeletal muscle using semi-quantitative western blotting and synthetic
mouse sarcolipin. Sarcolipin levels were so low that it is unlikely that knocking out sarcolipin would have
a measurable effect on thermogenesis by SERCA. In addition, overexpression of neither wild type nor
FLAG-tagged variants of mouse sarcolipin in transgenic mice had any major signiﬁcant effects on body
mass, energy expenditure, even when mice were fed on a high fat diet.
 2015 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).Introduction
Sarcolipin is a 31aa transmembranous peptide found in the sar-
coplasmic reticulum (SR)1 of skeletal muscle and cardiac atria that is
believed to play a role in the modulation of SR calcium pumps (SER-
CAs) [1,2]. In addition to altering the kinetics of calcium transport,
in vitro studies indicate that sarcolipin can partially uncouple calci-
um transport from ATP hydrolysis by these pumps, causing
enhanced thermogenesis [3,4].
In a recent sarcolipin knockout (SLN/) study in mice, it was
reported that sarcolipin was protective against hypothermia and
obesity induced by a high fat diet; these effects were attributed
to muscle-based thermogenesis, through the inﬂuence of sarcol-
ipin on SERCA [5,6]. These ﬁndings are in line with the thermo-
genic effects of sarcolipin on the activity of SERCA observed
in vitro [4]. However, an analysis of sarcolipin levels in the skele-
tal muscles of a range of mammals indicated that while large
mammals such as pigs and rabbits have relatively large amounts
of sarcolipin in their skeletal muscle, in smaller species, such asmice and rats, sarcolipin was undetectable [7]. Although sarcolip-
in has been detected in mouse skeletal muscle in other studies
(see [5,8,9]), the levels of sarcolipin have not been quantiﬁed.
This suggests that sarcolipin may have a role in muscle-based
thermogenesis in larger mammals, whereas in smaller mammals
its role in thermogenesis is less clear. It has also been reported
that while sarcolipin ablation increased the stoichiometry of cal-
cium uptake/ATP hydrolysed by SERCA from mouse soleus, sup-
porting a role for sarcolipin in thermogenesis, the resting
oxygen consumption by soleus was unaffected by sarcolipin abla-
tion [10].
We have sought to resolve the discrepancy in the detection
of sarcolipin in mouse muscle by using semi-quantitative west-
ern blotting to estimate the ratio of sarcolipin to SERCA in the
SR of mouse skeletal muscle from mouse strains C57BL/6, the
strain used in the sarcolipin knockout study [5], and FVBN,
which is used here to produce transgenic mice over-expressing
sarcolipin. In addition, in view of the previous study indicating
that sarcolipin levels are undetectable in mouse skeletal muscle
[7], which suggests that there is little value in knocking out sar-
colipin, we have examined the effects of over-expressing sarcol-
ipin and an epitope-tagged (FLAG) variant of sarcolipin in mouse
skeletal muscle on high fat diet-induced obesity and energy
expenditure.
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Animals
All procedures were conducted in accordance with the
University of Southampton and University of Buckingham Home
Ofﬁce UK project licences under the Animals (Scientiﬁc
Procedures) Act (1986).Production of transgenic mice
A DNA sequence encoding mouse sarcolipin was obtained as
described previously [11]. The mouse sequence was ampliﬁed by
the polymerase chain reaction (PCR) using oligonucleotides
atggaaaggtctactcaagagctg and agatcagtactggtaagaccgcactag to pro-
duce a sequence coding for the wild type protein, and aaggacgac-
gacgacaaggaaaggtctactcaagagctgttc and atggactacaaggacgacgacg
acaaggaaaggtctac to produce a sequence coding for sarcolipin
tagged with the FLAG epitope [12] at its N-terminus. The resulting
PCR products were ligated into plasmid pSKMHSApA (provided by
Dr. Edna Hardeman, University of New South Wales, Australia)
consisting of the human skeletal actin (HSA) promoter, a splice
acceptance site and two SV40 polyadenylation signal sequences
[13]. Recombinants were cloned and sequenced and the insert
ﬂanked by HSA promoter and polyadenylation signals was released
with NotI, gel puriﬁed and injected into FVB/N embryos. Both the
sarcolipin founder and FLAG-SLN founder were bred to homozy-
gosity to enhance the levels of transgene expression.Animal procedures
Mice were fed on a standard chow diet that contained 10% fat,
70% carbohydrate and 20% protein by energy (RM1; Beekay Feed,
B&K Universal Ltd., Hull, UK), until they were 11 weeks old and
then on a high fat diet that contained, by energy, 60% fat, 20% car-
bohydrate and 20% protein (D12492; Research Diets, New
Brunswick, USA). They were housed at 22 C with lights off from
07.00 to 19.00 h. Fourteen male mice of each genotype (wild type
FVBN, Sln+/+, and FLAG-tagged Sln+/+) were housed in pairs. Food
intake for each cage of mice was measured over 24 h when the
mice were 10, 11 and (after being on the high fat diet for a week)
12 weeks old. Body weight was measured weekly. Energy expendi-
ture was measured by open circuit indirect calorimetry in their
home cages as described previously [14] at 10 weeks of age when
the mice were eating standard chow and again at 26 weeks of age
after they had been switched to the high fat diet.Preparation of sarcoplasmic reticulum from mouse skeletal muscle
SR was prepared using a modiﬁcation of a method previously
described [15]. The procedure was carried out at 4 C. Skeletal
muscle stripped from the fore and hind limbs was chopped and
homogenised using a glass/Teﬂon homogeniser in 4 volumes of
0.1 M NaCl, 10 mM MOPS-Tris, pH 7.0. The homogenate was cen-
trifuged at 8300g for 20 min and the supernatant centrifuged for
a further 30 min at 12,000g for 30 min. The resulting supernatant
was centrifuged at 53,000g for 40 min and the pellet was resus-
pended in 40 volumes of 0.6 M KCl, 5 mM Tris-maleate, pH 6.5
and stirred for 40 min. The suspension was then centrifuged at
125,000g for 45 min; the pellet was rinsed in 0.1 M sucrose,
30 mM MOPS-Tris, pH 7.0 then resuspended in the same buffer,
snap frozen in liquid nitrogen and stored at 70 C. Protein was
measured using a DC protein assay kit (Bio-Rad).Semi-quantitative western blotting
Mouse skeletal muscle was homogenised in 300 mM sucrose,
10 mM imidazole pH 7.0 with the addition of protease inhibitor
cocktail 1:100 (Sigma). Protein concentration was determined
using a DC protein assay (Biorad). Homogenates were snap frozen
and stored at 80 C. All SDS–PAGE was carried out using 10–20%
tricine gels (Invitrogen). The protein was transferred to PVDF
membranes 0.2 micron pore size (GE Healthcare) and blocked
overnight in 20 mM Tris, 150 mM NaCl (TBS) containing 5% bovine
serum albumin (BSA). Western blotting of sarcolipin was carried
out using either a primary antibody raised to sarcolipin peptide
sequence VRSYGY in rabbit (a gift from Dr. Muthu Periasamy, Ohio
State University) used at 1:1000 or from Millipore (Anti-Sarcolipin
Antibody ABT13). Western blotting of SERCA was performed using
the pan-SERCA rabbit polyclonal antibody (a gift from Peter Van-
gheluwe, K.U. Leuven, Belgium). Primary antibodies were detected
using an IRDye goat polyclonal anti rabbit 800 nm conjugated anti-
body 1:10,000 (LI-COR) or IREDye goat polyclonal anti mouse
800 nm conjugate antibody 1:10,000 (LI-COR). The blots were
detected and analysed using the LI-COR ODYSSEY detection
system.
Immunolocalistion of FLAG-SLN
Mouse skeletal muscle was snap frozen and sectioned (6 lm)
using a Cryostat. Sections were collected onto poly L-lysine coated
glass slides; ﬁxed in acetone20 C for 10 min; washed in 137 mM
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2.0 mM KH2PO4, 0.1% Triton X-
100, pH 7.4 (PBST) and blocked for 1 h in PBST containing 10% BSA.
Anti-FLAG-FITC conjugate antibody was incubated at 1:100
(Abcam 1259) and rabbit polyclonal anti-SERCA 1/2/3 incubated
at 1:100 (Santa Cruz Biotechnology, H-300 SC-30110) overnight
at 4 C. The primary antibodies were washed off with PBST and
the anti SERCA primary antibody was detected using anti-rabbit
Texas red conjugate raised in donkey 1:100 (GE Healthcare). The
secondary antibody was washed off with PBST and the tissue incu-
bated with DAPI stain (5 mg/ml diluted 1:5000 for working
strength). Tissue was washed and then mounted using Mowiol
mountant containing 0.1% citiﬂuor anti-bleaching agent. Samples
were viewed with a Leica TCS SP2 confocal microscope under oil
with a 40 objective and pinhole diameter of Airy 1. Leica LCS soft-
ware was used for image acquisition and analysis. Fluorescein was
excited at a wavelength of 490 nm and emission was measured
between 500 and 600 nm and Texas Red was excited at 594 nm
and emission was measured between 605 and 700 nm.
Statistics
Body weight, food intake and energy expenditure data were
analysed by one-way analysis of variance at each age, followed
by Dunnett’s multiple comparison test. Bartlett’s test showed no
signiﬁcant differences in variances between the three genotypes.
A repeated measures two-way analysis of variance followed by
Bonferroni post-tests with the control group was also conducted
on the body weight data for animals from 10 to 28 weeks of age,
and on the food intake measurements.Results and discussion
The study of Vangheluwe et al. [7] indicates that the levels of
sarcolipin in mice are below the level of detection. Therefore, in
this study, instead of knocking out the sarcolipin gene, transgenic
mice were created using constructs under the control of the human
skeletal actin promoter in order to over-express wild type mouse
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[13]. The FLAG tag was employed so that it would be possible to
validate sarcolipin incorporation into to the sarcoplasmic reticu-
lum; sarcolipin antibodies are ineffective in immunoﬂuorescence
microscopy.
In addition, using synthetic sarcolipin and semi-quantitative
western blotting, the levels of sarcolipin expression were deter-
mined in the skeletal muscle of transgenic animals as well as in
wild-type mice. The wild-type strains were both FVBN (used in this
study) and C57BL/6 (used for the sarcolipin knockout studies
reported previously [5,6]).
The semi-quantitative western blotting method using synthetic
mouse sarcolipin was validated by estimating the levels of sarcol-
ipin in the atria of FVBN mice. Fig. 1A is a western blot showing a
comparison of the content of sarcolipin in 30 lg of mouse atria in
lane 4 with 25, 5.0 and 2.5 ng of synthetic sarcolipin (lanes 1–3
respectively). Sarcolipin migrates by SDS–PAGE with an apparent
Mr of 4000. The amount of sarcolipin in 30 lg of atrial tissue is
approximately 9 ng. Using the estimate of SERCA obtained by
western blotting of 14 lg/mg atrial tissue (data not shown), which
is comparable to the value of 10 lg SERCA/mg atrial tissue
obtained by [7]), this gives a molar ratio of 0.50 mol sarcolipin/mol
SERCA. This value is similar to that previously reported: 1.24 mol
sarcolipin/mol SERCA [7]. Similarly the blot shown in Fig. 1B com-
pares 1 lg of rabbit total skeletal muscle SR (lane 4) with 20, 40
and 60 ng synthetic mouse sarcolipin (lanes 1–3 respectively).
One microgram of SR contains approximately 27 ng sarcolipin.
These data give a value of 1.2 mol sarcolipin/mol SERCA, assuming
that rabbit muscle SR contains 70% SERCA (estimated from SDS–
PAGE of SR stained with SYPRO orange). This is similar to the val-
ues previously reported for rabbit soleus and extensor digitorum
longus muscles of 0.87 and 0.37 mol sarcolipin/mol SERCA respec-Fig. 1. (A) Characterisation of sarcolipin levels in mouse atria and rabbit skeletal
muscle by semi-quantitative western blotting. 30 lg (protein) of homogenised
pooled left and right atrial tissue from 8 to 10 week old FVBN mice was separated
by SDS–PAGE (lane 4) and synthetic sarcolipin, 20, 5.0 and 2.5 ng of peptide were
included as standards (lanes 1, 2 and 3 respectively). Following the transfer of the
proteins from the gel to PVDF membranes the blots were probed with anti-
sarcolipin antibody, followed by a goat anti-rabbit ﬂuorophore conjugated anti-
body. (B) SR, 1 lg, from a 3 kg New Zealand white rabbit was separated by SDS–
PAGE (lane 4) and synthetic sarcolipin, 20, 40 and 60 ng (lanes 1–3). The blots were
visualised and analysed using the LI-COR ODYSSEY detection system. Blots shown
are typical of at least two determinations.tively [7]. Even though the sequences of rabbit and mouse sarcol-
ipin are different, the use of an antibody against the mouse
sarcolipin sequence to quantify the rabbit homologue is justiﬁed
because the antibody is raised against the peptide VRSYQY, corre-
sponding to the C-terminal sequence of sarcolipin from numerous
mammalian species, including mouse, rabbit and human.
An examination of the sarcolipin levels in sarcoplasmic reticu-
lum from total skeletal muscle of FVBN mice conﬁrmed the ﬁnding
of Vangheluwe et al. [7] that sarcolipin was below the level of
detection in mouse skeletal muscle using western blotting tech-
niques (Fig. 2A; lane 2) though as little as 1 ng of synthetic sarcol-
ipin was detectable in this blot (lane 5). By contrast, the western
blot procedure was able to detect sarcolipin in the SR of transgenic
FVBN mice over-expressing this protein (lane 1). Sarcolipin knock-
out studies have been reported using C57BL6 mice [5,6,10], so the
level of sarcolipin in this strain of mice was also examined. Sarcol-
ipin was undetected by western blotting in homogenates of com-
bined limb skeletal muscle taken from this mouse strain (Fig. 2B,
lane 2), but FLAG-tagged sarcolipin and sarcolipin were readily
detectable in muscle homogenates of transgenic FVBN mice over-
expressing these proteins (lanes 1 and 3 respectively). The FLAG-
tagged sarcolipin migrated under SDS–PAGE with an apparent Mr
of around 6000. Previously, studies have shown that sarcolipin
can be detected in soleus muscle from C57/BL6 mice [5,8] however
the study by Bombardier et al. [10] clearly shows that the sarcolip-
in content of 100 lg of soleus is far less, by some considerable mar-
gin, than that contained by 1 lg of atrial tissue. Given that limb
skeletal muscles such as white gastrocnemius, extensor digitorumFig. 2. Expression of sarcolipin and FLAG-tagged sarcolipin in the skeletal muscle of
transgenic and control mice detected by western blotting. (A) 40 lg (protein) of
sarcoplasmic reticulum from sarcolipin+/+ transgenic mice and FVBN control mice
(from total limb skeletal muscle) were separated by SDS–PAGE (lanes 1 and 2,
respectively). Synthetic sarcolipin, 10, 5 and 1 ng of peptide were included as
standards (lanes 3, 4 and 5, respectively). (B) 100 lg of homogenised total limb
skeletal muscle from FLAG-tagged sarcolipin+/+, C57BL/6 and sarcolipin+/+ mice
were separated by SDS–PAGE (lanes 1, 2 and 3, respectively). (C) 40 lg (protein) of
sarcoplasmic reticulum from sarcolipin+/+ and FLAG-tagged sarcolipin+/+ transgenic
mice (from total limb skeletal muscle) were separated by SDS–PAGE (lanes 3 and 4,
respectively). Synthetic sarcolipin, 20 and 40 ng of peptide were included as
standards (lanes 1 and 2). All mice used for the analyses above were aged 8–
10 weeks (D) 120 lg (protein) of homogenised soleus muscle from 30 week old
FVBN mice was separated by SDS–PAGE; mice were fed on the high fat diet from
week 11–30 weeks (lane 3) or a standard chow diet throughout (lane 4). Synthetic
sarcolipin, 1.0, 2.0 and 3 ng of peptide were included as standards (lanes 1, 2 and 5,
respectively). In all cases, following the transfer of the proteins from the gel to PVDF
membranes the blots were probed with anti-sarcolipin antibody, followed by a goat
anti-rabbit ﬂuorophore conjugated antibody. The blots were visualised and
analysed using the LI-COR ODYSSEY detection system. Blots shown are typical of
at least two determinations.
Fig. 3. Immunolocalisation of SERCA and FLAG-tagged sarcolipin in mouse skeletal muscle. Frozen sections of skeletal muscle from transgenic mice expressing FLAG-tagged
sarcolipin were acetone ﬁxed, blocked for 1 h in PBST containing 10% BSA. The sections were then incubated with Anti-FLAG-FITC conjugate antibody (1:100) rabbit
polyclonal anti-SERCA1/2/3 (1:100) (Santa Cruz). The primary antibodies were detected using donkey anti-rabbit Texas red conjugate (1:100). Following washing the section
was incubated with DAPI stain 1 lg/ml and mounted in Mowiol containing 0.1% citiﬂuor. FITC ﬂuorescence is shown in panel A; Texas red ﬂuorescence in panel B; DAPI
ﬂuorescence in panel C and FITC, DAPI and Texas red merged in panel D.
Fig. 4. Effect of high fat diet on the body weight of sarcolipin over-expressing and
FLAG-tagged sarcolipin expressing mice. (A) Male wild type (s, solid line),
sarcolipin over-expressing (N, dashed line) and FLAG-tagged sarcolipin expressing
(., dotted line) mice were fed on a standard chow diet until 11 weeks of age after
which they were transferred onto a high fat (60%) diet. Body weight was measured
on a weekly basis. The bars indicate standard error of the mean, n = 14. ⁄P < 0.05 for
FLAG-sarcolipin overexpressing mice compared to control mice by one-way ANOVA
followed by Dunnett’s test at 22 and 26 weeks of age. (B, inset) Food intake was
measured during the transition from standard chow to high fat diet. The bars
indicate standard error of the mean, n = 14. ⁄P < 0.05 for FLAG-sarcolipin overex-
pressing mice compared to control mice by two-way ANOVA followed by
Bonferroni multiple comparisons test.
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sarcolipin is diluted to such an extent that it is difﬁcult to detect
when C57/BL6 limb muscle is combined as in Fig. 2B. Soleusappears to be one of the limb skeletal muscles containing the high-
est levels of sarcolipin in mouse [8,9,16]. In this study the level of
sarcolipin in 120 lg of homogenised soleus from 30 week old male
FVBN mice was not detectable (Fig. 2D, lane 4) and was certainly
less than 1 ng sarcolipin, which is just detectable (lane 1). Using
the value for SERCA in soleus homogenates determined by western
blotting of 21 lg SERCA/mg protein (data nor shown), which is
comparable with the value from [7] of 16 lg SERCA/mg protein,
the sarcolipin level in soleus is <0.012 mol sarcolipin/mol SERCA.
Although Bombardier et al. [10] were able to demonstrate the pres-
ence of sarcolipin in wild type soleus this was close to the limits of
detection, requiring an enhancement of the image. As previously
described [6], the high fat diet did increase the level of sarcolipin
in mouse soleus muscle. In Fig. 2D (lane 3) 120 lg of homogenised
soleus from 30-week-old male FVBN mice fed on a high fat diet
(lane 3) contained around 2 ng sarcolipin (2 ng sarcolipin standard
in lane 2), which translates to 0.023 mol sarcolipin/mol SERCA.
These data indicate that the level of sarcolipin in mouse muscle
is so low as to make it likely that any direct effect of sarcolipin on
SERCA function [3,4] would be small and hence the effect of knock-
ing it out would be difﬁcult to detect.
The levels of mouse sarcolipin and FLAG-tagged sarcolipin in SR
obtained from transgenic animals were calculated from the west-
ern blot shown in Fig. 2C. Using the sarcolipin standards in lanes
2 and 3 (20 and 40 ng sarcolipin respectively) and a value of 50%
SERCA in mouse SR estimated from SDS–PAGE gels of SR stained
with SYPRO orange (data not shown), the sarcolipin/SERCA ratios
were estimated to be 0.037 mol sarcolipin/mol SERCA and
0.059 mol FLAG-tagged sarcolipin/mol SERCA. The levels of these
transgenically-expressed proteins are still low compared to the
levels in mouse atria and rabbit SR, where the value is close to
1 mol sarcolipin/mol SERCA.
Fig. 5. Effect of sarcolipin over-expression and FLAG-sarcolipin expression by skeletal muscle on metabolic rate. Hourly energy expenditure 1 week before (A) and 15 weeks
after (B) the introduction of the high fat diet in male wild type (solid line), sarcolipin over-expressing (dashed line) and FLAG-tagged sarcolipin expressing (dotted line). Error
bars have been omitted for clarity since the objective is to show that the diurnal rhythm of energy expenditure was similar in all genotypes Total energy expenditure over
24 h at 10 weeks of age and over 22 h at 26 weeks of age is shown in (A inset) and (B inset) respectively; n = 7 cages. There were no signiﬁcant differences in energy
expenditure at any hourly time point or in total.
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SERCA; the pattern of labelling was similar to that reported previ-
ously for the related SERCA modulatory peptide phospholamban
[17], indicating that the FLAG-tagged sarcolipin was, and by infer-
ence the untagged construct would be, appropriately targeted to
the SR.
Since sarcolipin has been shown to cause the uncoupling of the
SERCA with which it is associated [3,4], one might predict that the
over-expression of sarcolipin would result in animals with a higher
energy expenditure, a reduced body mass and the potential to
mitigate the effects of a high fat diet. However, Fig. 4 shows that
there was no signiﬁcant difference in body masses between the
control animals and those expressing sarcolipin or FLAG-sarcolipin
transgenes at 10 or 11 weeks after birth (fed on standard chow).
After the animals were transferred to a high fat diet from 11 weeks
of age, FLAG-sarcolipin expressing animals tended to gain less
weight compared with control animals and SLN expressing mice,
and at 22 and 26 weeks of age their body weight was signiﬁcantly
lower than that of the control group. However, this difference was
not apparent at 30 weeks of age. Sarcolipin expressing mice mir-
rored the control animals when fed the high fat diet, showing no
signiﬁcant difference. Two-way analysis of variance of body
weights showed an effect of genotype on body weight (P < 0.05)
and an interaction between time and genotype (P < 0.01), consis-
tent with this observation, but Bonferroni tests did not show sig-
niﬁcant differences between genotypes at any age. Two-way
analysis of variance of body weight gain (data not shown) also
showed a signiﬁcant effect of genotype (P < 0.05), and in this case
Bonferroni tests did show signiﬁcant differences between the con-
trol and FLAG-SLN expressing animals, but only at 22 and 26 weeks
of age (P < 0.05 at both ages). There was no signiﬁcant difference
between the food intake of the three groups before transfer onto
the high fat diet, but repeated measures two-way ANOVA showed
a signiﬁcant interaction between time and genotype and a
Bonferroni test showed that food intake was signiﬁcantly lower
(P < 0.05) in the FLAG-SLN expressing than the control animals
after they were transferred to the high fat diet (Fig. 4 inset), consis-
tent with reduced weight gain in these animals.The ﬁnding that there are no major effects of over-expressing
sarcolipin and ﬂag-tagged sarcolipin on body mass as a result of
overfeeding is also reﬂected in the ﬁnding that energy expenditure,
measured by open circuit indirect calorimetry, was similar for both
wild type and transgenic animals (Fig. 5). There were no signiﬁcant
differences, either at 10 weeks of age (before the feeding of the
high fat diet) (Fig. 5A) or after 15 weeks on the high fat diet
(Fig. 5B), between wild type mice and mice over-expressing sarcol-
ipin or FLAG-tagged sarcolipin in either the diurnal rhythm (main
Fig. 5A and B) or in total energy expenditure (inset Fig. 5A and B),
whether data were expressed for the whole animal (as in Fig. 5) or
relative to body weight (data not shown).
Using the data provided by the in vitro investigation of the
effects of sarcolipin on heat production [4] it is evident that, if all
of the sarcolipin in the sarcolipin overexpressing mouse
(0.037 mol sarcolipin/mol SERCA) were bound to SERCA, DHwould
rise from approximately 5.9 kcal/mol hydrolysed to 6.0 kcal/mol,
i.e., a 1.7% increase in heat output. It is unlikely that such an effect
would be detectable.
Using the same argument, it is also unlikely that effects reported
for sarcolipin knockout mice, such as the loss of protection from
both hypothermia and obesity, induced by a high fat diet [5] can
be directly attributed to the direct effect of sarcolipin on the heat
output of SERCA. The amount of sarcolipin in the skeletal muscles
of these animals is so small (<0.0015 mol sarcolipin/mol SERCA for
FVBN mice and virtually undetectable in homogenates of total
skeletal muscle of C57BL6 mice) as to make the impact of its
removal on the heat production by SERCA close to zero. The cause
of the effect of sarcolipin knockout on thermogenesis in [5] is
unclear, but may be related to more subtle effects on calcium
signalling.
A deﬁnitive demonstration of the effects of sarcolipin on energy
expenditure in vitro, acting through a direct effect on, will require a
knockout experiment employing an animal, such as rabbit, which
has signiﬁcant levels of skeletal muscle sarcolipin. Knocking out
sarcolipin in rabbit skeletal muscle (from this study the value is
1.2 mol sarcolipin/mol SERCA) would result in a reduction in heat
output from approximately 7.6 kcal/mol to 5.9 kcal/mol (a drop
J. Butler et al. / Archives of Biochemistry and Biophysics 569 (2015) 26–31 31in heat output of 22% calculated using the data in [4]).
Alternatively, the creation of a transgenic mouse expressing near
stoichiometric amounts of sarcolipin relative to SERCA in skeletal
muscle would provide a useful comparator.
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